WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1393-1399

  Kerst, Gunter ^a   Bergold, Nina ^a   Viebahn, Susanne ^a   Gieseke, Friederike ^a   Kalinova, Marketa ^b   Trka, Jan ^b   Handgretinger, Rupert ^a   Müller, Ingo ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acute leukemia; Immunotherapy; Leukemic stem cells; Minimal residual disease; Wilms' tumor gene 1 (WT1)

Indexed keywords

WT1 PROTEIN;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; WT1 PROTEINS;

EID: 43149122869     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.006     Document Type: Article

References (48)

1. Miwa H., Beran M., and Saunders G.F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6 (1992) 405-409
2. Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89 (1997) 1405-1412
3. Trka J., Kalinova M., Hrusak O., Zuna J., Krejci O., Madzo J., et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16 (2002) 1381-1389
4. Cilloni D., and Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112 (2004) 79-84
5. Ostergaard M., Olesen L.H., Hasle H., Kjeldsen E., and Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 125 (2004) 590-600
6. Tamaki H., Ogawa H., Ohyashiki K., Ohyashiki J.H., Iwama H., Inoue K., et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13 (1999) 393-399
7. Cilloni D., Gottardi E., Messa F., Fava M., Scaravaglio P., Bertini M., et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 21 (2003) 1988-1995
8. Algar E.M., Khromykh T., Smith S.I., Blackburn D.M., Bryson G.J., and Smith P.J. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12 (1996) 1005-1014
9. Hossain A., Nixon M., Kuo M.T., and Saunders G.F. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J Biol Chem (2006)
10. Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87 (1996) 2878-2884
11. King-Underwood L., and Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 91 (1998) 2961-2968
12. King-Underwood L., Renshaw J., and Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 87 (1996) 2171-2179
13. Van Dijk J.P., Knops G.H., Van De Locht L.T., Menke A.L., Jansen J.H., Mensink E.J., et al. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. Br J Haematol 118 (2002) 1027-1033
14. Baird P.N., and Simmons P.J. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25 (1997) 312-320
15. Ellisen L.W., Carlesso N., Cheng T., Scadden D.T., and Haber D.A. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 20 (2001) 1897-1909
16. Barragan E., Cervera J., Bolufer P., Ballester S., Martin G., Fernandez P., et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89 (2004) 926-933
17. Siehl J.M., Thiel E., Heufelder K., Snarski E., Schwartz S., Mailander V., et al. Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol 123 (2003) 235-242
18. Scharnhorst V., van der Eb A.J., and Jochemsen A.G. WT1 proteins: functions in growth and differentiation. Gene 273 (2001) 141-161
19. Loeb D.M., Summers J.L., Burwell E.A., Korz D., Friedman A.D., and Sukumar S. An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. Leukemia 17 (2003) 965-971
20. Ellisen L.W. Regulation of gene expression by WT1 in development and tumorigenesis. Int J Hematol 76 (2002) 110-116
21. Bruening W., and Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. J Biol Chem 271 (1996) 8646-8654
22. Dechsukhum C., Ware J.L., Ferreira-Gonzalez A., Wilkinson D.S., and Garrett C.T. Detection of a novel truncated WT1 transcript in human neoplasia. Mol Diagn 5 (2000) 117-128
23. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84 (1994) 3071-3079
24. Uzunel M., and Ringden O. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transpl 33 (2004) 47-52
25. Ogawa H., Tamaki H., Ikegame K., Soma T., Kawakami M., Tsuboi A., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101 (2003) 1698-1704
26. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16 (2002) 2115-2121
27. Mailander V., Scheibenbogen C., Thiel E., Letsch A., Blau I.W., and Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18 (2004) 165-166
28. Tsuboi A., Oka Y., Udaka K., Murakami M., Masuda T., Nakano A., et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51 (2002) 614-620
29. Keilholz U., Menssen H.D., Gaiger A., Menke A., Oji Y., Oka Y., et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 19 (2005) 1318-1323
30. Gao L., Bellantuono I., Elsasser A., Marley S.B., Gordon M.Y., Goldman J.M., et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95 (2000) 2198-2203
31. Gao L., Xue S.A., Hasserjian R., Cotter F., Kaeda J., Goldman J.M., et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75 (2003) 1429-1436
32. Bellantuono I., Gao L., Parry S., Marley S., Dazzi F., Apperley J., et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100 (2002) 3835-3837
33. Oka Y., Udaka K., Tsuboi A., Elisseeva O.A., Ogawa H., Aozasa K., et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164 (2000) 1873-1880
34. Campana D. Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 18 (1994) 68-74
35. Campana D., and Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 38 (1999) 139-152
36. Coustan-Smith E., Sancho J., Hancock M.L., Boyett J.M., Behm F.G., Raimondi S.C., et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96 (2000) 2691-2696
37. Chen J.S., Coustan-Smith E., Suzuki T., Neale G.A., Mihara K., Pui C.H., et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 97 (2001) 2115-2120
38. Campana D., and Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15 (2002) 1-19
39. Kerst G.*., Kreyenberg H.*., Roth C., Well C., Dietz K., Coustan-Smith E., et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 128 (2005) 774-782
40. Darzynkiewicz Z., Gong J., Juan G., Ardelt B., and Traganos F. Cytometry of cyclin proteins. Cytometry 25 (1996) 1-13
41. Yamagami T., Ogawa H., Tamaki H., Oji Y., Soma T., Oka Y., et al. Suppression of Wilms' tumor gene (WT1) expression induces G2/M arrest in leukemic cells. Leuk Res 22 (1998) 383-384
42. Kudoh T., Ishidate T., Moriyama M., Toyoshima K., and Akiyama T. G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. Proc Natl Acad Sci USA 92 (1995) 4517-4521
43. Dobashi Y., Kudoh T., Ishidate T., Shoji M., Toyoshima K., and Akiyama T. The Wilms tumor protein is persistently associated with the nuclear matrix throughout the cell cycle. Mol Cell Biochem 171 (1997) 121-126
44. Tuna M., Chavez-Reyes A., and Tari A.M. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 24 (2005) 1648-1652
45. Olszewski M., Huang W., Chou P.M., Duerst R., and Kletzel M. Wilms' tumor 1 (WT1) gene in hematopoiesis: a surrogate marker of cell proliferation as a possible mechanism of action?. Cytotherapy 7 (2005) 57-61
46. Ravandi F., and Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 12 (2006) 340-344
47. Wulf G.G., Wang R.Y., Kuehnle I., Weidner D., Marini F., Brenner M.K., et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98 (2001) 1166-1173
48. Kerst G., Bergold N., Gieseke F., Coustan-Smith E., Lang P., Kalinova M., et al. WT1 protein expression in childhood acute leukemia. Am J Hematol 83 (2008) 382-386